Liposomal cytarabine and daunorubicin (CPX-351/Vyxeos)–associated distinct purpuric subtype of toxic erythema of chemotherapy: A retrospective review of 54 patients - 09/12/21
Graphical abstract |
Drs Taylor and Markova contributed equally to this article. |
|
Funding sources: Dr Markova was supported by a Dermatology Foundation Career Development Award. This study was also funded in part by a grant from the National Cancer Institute/National Institutes of Health (P30-CA008748) made to the Memorial Sloan Kettering Cancer Center. |
|
IRB approval status: Reviewed and approved by the IRB of Memorial Sloan Kettering Cancer Center. |
Vol 86 - N° 1
P. 232-234 - janvier 2022 Retour au numéroBienvenue sur EM-consulte, la référence des professionnels de santé.
L’accès au texte intégral de cet article nécessite un abonnement.
Déjà abonné à cette revue ?